

# ANSWERS FOR CANCER

# Genetron Health to Present at Six Upcoming Investor and Industry Conferences

October 29, 2020

BEIJING, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present and host 1x1 investor meetings at six upcoming investor and industry conferences.

Details related to the team's participation are as follows:

Conference: China Renaissance Healthcare and Life Sciences Leadership Summit

Location: Shanghai, China

Roundtable Discussion: October 30 at 11:55 am CST (China Standard Time)

Conference: CICC Investment Forum (Beijing) 2020

Location: Beijing, China

Panel Discussion Date & Time: November 12 at 3:30 pm CST

Conference: BioCentury and BayHelix 7th China Healthcare Summit

Dates: November 9-13

Conference: Goldman Sachs Asia Pacific Healthcare Conference 2020

Dates: November 16-17

Conference: Bernstein's Inaugural Operational Decisions Conference (ODC)
Presentation Date/Time: November 17 at 10:00 am EST (Eastern Standard Time)

Conference: Canaccord Genuity's MedTech and Diagnostics Forum

Presentation Date/Time: November 19 at 8:30 am EST

### **About Genetron Holdings Limited**

Genetron Holdings Limited ("Genetron Health" or the "Company") (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

#### Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may", "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

### **Investor Relations Contacts**

<u>US:</u> Hoki Luk

Head of Investor Relations

Email: hoki.luk@genetronhealth.com

Phone: +1 (408) 204-5343

Stephanie Carrington

Westwicke, an ICR Company

Email: Stephanie.Carrington@westwicke.com

Phone: +1 (646) 277-1282

Asia: Bill Zima ICR, Inc.

Email: bill.zima@icrinc.com GenetronIR@icrinc.com

# **Media Relations Contact**

Edmond Lococo ICR

Edmond.Lococo@icrinc.com Mobile: +86 138-1079-1408

genetron.pr@icrinc.com